Simcere Pharmaceutical Group Full Year 2024 Earnings: EPS Misses Expectations

Simcere Pharmaceutical Group (HKG:2096) Full Year 2024 Results

Key Financial Results

• Revenue: CN¥6.64b (flat on FY 2023).
• Net income: CN¥733.2m (up 2.6% from FY 2023).
• Profit margin: 11% (in line with FY 2023).
• EPS: CN¥0.29 (up from CN¥0.27 in FY 2023).

2096 Products In Clinical Trials

• Phase I: 11.
• Phase II: 2.
• Phase III: 9.

2096 Post-Clinical Trial Products

• Pre-registration: 2.
• Approved (during full year): 3.
• Launched (during full year): 1.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Simcere Pharmaceutical Group EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 16%.

In the last 12 months, the only revenue segment was Pharmaceuticals contributing CN¥6.64b. The largest operating expense was Sales & Marketing costs, amounting to CN¥2.51b (55% of total expenses). Explore how 2096's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Pharmaceuticals industry in Hong Kong.

Performance of the Hong Kong Pharmaceuticals industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

Before we wrap up, we've discovered 1 warning sign for Simcere Pharmaceutical Group that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.